Stock PLX PROTALIX BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE

Equities

PLX

US74365A3095

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 11:24:48 2023-03-21 EDT 		5-day change 1st Jan Change
732.5 ILa -.--% Intraday chart for Protalix BioTherapeutics, Inc. +3.29% +69.68%
05-10 Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024
05-10 Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Protalix BioTherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5763.o9dPzuItlED262nLYk-kF2z_OUcoDq_Y7uM78hxrZBE.75gbtNFk-3eCtCepIAuQOh-xaCxCS9X137deqko-LGHzoQasjgDfN7iPOA~28ec762e4cc8d6692c9f2b054a696165

Analyst Recommendations on Protalix BioTherapeutics, Inc.

HC Wainwright Adjusts Protalix BioTherapeutics' Price Target to $10 From $7, Keeps Buy Rating MT
PROTALIX BIOTHERAPEUTICS : HC Wainwright Adjusts Price Target on Protalix BioTherapeutics to $7 From $11, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.13 USD
Average target price
12 USD
Spread / Average Target
+961.95%
High Price Target
14 USD
Spread / Highest target
+1,138.94%
Low Price Target
10 USD
Spread / Lowest Target
+784.96%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Protalix BioTherapeutics, Inc.

HC Wainwright

Ratings for Protalix BioTherapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PLX Stock
  4. PLX Stock
  5. Consensus Protalix BioTherapeutics, Inc.